This list is based on the watchlists of people on Stock Events who follow 7BG.STU. It's not an investment recommendation.
This list is an analysis based on recent market events. It's not an investment recommendation.
BerGenBio ASA is a clinical-stage biopharmaceutical firm dedicated to discovering and advancing therapies for challenging conditions. This includes cancers that are immune-evasive, drug-resistant, or metastatic, as well as various respiratory diseases. Its leading drug candidate, Bemcentinib, is an orally available, small molecule AXL inhibitor that has progressed to Phase II clinical development. This involves studies across several significant cancer indications and for COVID-19. Specifically, its Phase II trials are focused on treating non-small cell lung cancer, acute myeloid leukemia, myelodysplastic syndrome, and COVID-19. Another promising compound in its pipeline is tilvestamab, an anti-AXL antibody currently undergoing Phase Ib clinical evaluation. The company maintains a collaborative agreement with Merck & Co. concerning its clinical trial initiatives. Founded in 2007, BerGenBio ASA is headquartered in Bergen, Norway.
Show more...
FAQ
What is Oncoinvent ASA. stock price today?▼
The current price of 7BG.STU is €8.60 EUR — it has increased by +6.17% in the past 24 hours. Watch Oncoinvent ASA. stock price performance more closely on the chart.
What is Oncoinvent ASA. stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on Boerse Stuttgart exchange Oncoinvent ASA. stocks are traded under the ticker 7BG.STU.
How many employees does Oncoinvent ASA. have?▼
As of September 05, 2026, the company has 13 employees.
In which sector is Oncoinvent ASA. located?▼
Oncoinvent ASA. operates in the Health & Wellness sector.
When did Oncoinvent ASA. complete a stock split?▼
The last stock split for Oncoinvent ASA. was on January 20, 2026 with a ratio of 1:100.
Where is Oncoinvent ASA. headquartered?▼
Oncoinvent ASA. is headquartered in Bergen, Other.